(Q28364123)

2

0 references

C Truffot-Pernot

3

0 references

B Ji

4

0 references

R J O'Brien

5

0 references

A Vernon

6

0 references

G Roscigno

7

0 references

J Grosset

Antimicrobial Agents and Chemotherapy

8

0 references

language of work or name

English

0 references

publication date

December 2001

0 references

published in

0 references

volume

45

0 references

issue

12

0 references

page(s)

3482-6

0 references

cites work

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Statistics in practice. Comparing the means of several groups.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=90857

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice

27 November 2018

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

1 reference

12 December 2020

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species

1 reference

12 December 2020

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

12 December 2020

Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone

1 reference

12 December 2020

Late results of long-term, intermittent chemotherapy of advanced, murine tuberculosis: Limits of the murine model

1 reference

12 December 2020